Interview: Luis Almeida, CEO, Luzitin, Portugal
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology,…
Luzitin, S.A. is an early-stage pharmaceutical company focused on investigating and developing innovative compounds to be used in Photodynamic Therapy (PDT) or Photodiagnosis (PDx) of cancer or other diseases, thus contributing to the human wellness.
Luzitin emerged as a spin-off company from an R&D partnership between Bluepharma, S.A. and the University of Coimbra, Portugal. The Luzitin’s starting intellectual property is a series of new photosensitizing drugs licensed-in from the University of Coimbra. In March 2011, these new photosensitizers have been awarded the INVENTA Prize, which honoured the most relevant Portuguese invention of the 2001-2010 decade.
Luzitin’s shareholders are Bluepharma, S.A., a venture capital firm (Portugal Ventures, S.A.), and the inventors of the patented drugs. Luzitin’s headquarters are located at S Martinho do Bispo, Coimbra, Portugal. Luis Almeida, MD, PhD (Chief Executive Officer), Luis Arnaut, PhD (Chief Scientific Officer), and Sérgio Simões, PharmD, PhD (Chairman), compose the Management Team (MT). All have over 20 years of experience in their fields, and altogether they cover all disciplines involved in drug R&D from bench to bedside.
Luzitin’s long-term goal is to become a leader in PDT or PDx of cancer and other selected indications by providing innovative products and services, and partnering with other companies and public research institutions to bring new products to market.
Luzitin is committed to reach proof-of-concept clinical trials (phase II) and afterwards to negotiate licensing terms with a pharmaceutical company to further co-develop and co-market its compounds.
Contact:
Luzitin, SA
Edifício Bluepharma – Rua da Bayer – S. Martinho do Bispo
3045-016 Coimbra
PORTUGAL
Phone: +351 239 800 300
Fax: +351 239 800 333
www.luzitin.pt
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology,…
Boehringer Ingelheim has a 60-year history in Portugal and, despite challenges in terms of market access and reimbursement delays, remains fully committed to providing innovative healthcare solutions in the country.…
From software development to sales and consultancy, Alexandre Leiria today heads up the Life Sciences, Healthcare, and Manufacturing arm of digital-focused consultancy Capgemini in Portugal. He discusses Capgemini’s role in…
Dr João Filipe Raposo outlines the importance of a collaborative, multidisciplinary approach to diabetes care management, an approach embodied by the APDP – Diabetes Portugal. He also touches on the…
Nuno Sousa details the development of Portugal’s clinical research ecosystem, highlighting the creation of the Clinical Academic Center of Braga (2CA-Braga) and its evolution. He emphasises the necessity of building…
Joana Branco of Biocant Park, Portugal’s pioneering biotech hub, delves into its strategic development and international impact since 2005. Branco highlights Biocant’s role in advancing the Portuguese life sciences sector,…
APDP is the association for people living with diabetes in Portugal, and the oldest such institution in the world. Deputy Clinical Director Dr Carolina Neves emphasises the APDP’s patient-centred approach…
Marco Dietrich highlights some of the key challenges in Portugal’s healthcare system, Bayer Portugal’s continuing focus on introducing new products – particularly in diabetes, where Portugal has the highest prevalence…
A staunch advocate for diversity and inclusion, Helena Freitas today leads the Portuguese affiliate of Sanofi, consistently ranked among the leading pharmaceutical firms in the country. With a focus on…
Pfizer holds a prominent position in Portugal’s pharmaceutical landscape, especially in the hospital business and for COVID-19-related products, with the emphasis now on sustainable growth post-COVID. Paulo Teixeira, a 26-year…
Ana Fereira highlights how the twin factors of people and time have shaped her leadership approach, how she is navigating the challenging generic medicines landscape in Portugal, and why STADA…
Mario Martins lays out IQVIA Portugal’s holistic approach to the healthcare sector, covering clinical trials, therapeutic studies, and technology solutions such as compliance CRM and quality control for manufacturing plants.…
Health Cluster Portugal is currently spearheading a EUR 90 million EU post-COVID Recovery and Resilience Plan (RRP) project in Portugal focused on smart health, secondary use of data, and clinical…
See our Cookie Privacy Policy Here
